Consequently, Equillium is planning to conduct a global, randomized, controlled clinical study of itolizumab in COVID-19 patients, for which it will file an investigational new drug application (IND) in the United States.Amgen made the investment through purchase of BeiGene's registered direct offering of ordinary shares to certain existing investors, announced by the company earlier this week.